


WELBLU - Cure for Dengue Serotypes

Innovative Solution: Drug – Device Integrated Emerging Technology

Dengue : Challenges & Opportunity



141 countries affected by the most rapidly resulting in **36,000 fatalities**

A 30-fold increase in global incidence over the past 50 years – No definitive treatment available till date

The expected market value in 2023 - 2033 is - **\$ 877.82 Million - \$ 5435.25 Million**


Project : WELBLU Overview

	Disease Category		Neglected I	Disease; On Priority list - Work	d Health Organization									
Product Overview	Segment	Public Health	Vector Borne	Viral Infection	Neglected Diseases	Emergency status								
	Platform	Emerging Technology: Drug - Device												
	Regulatory Classification	New Drug Application - Fast Track Review												
1	WELBLU	Repurposed Sublingual Drug formulation integrated with low wavelength visible light device												
ct Overview	Action on Dengue Serotype	Dual Action : Disintegrate the Lipid Envelope & Modulate Host immune Cytokine Storm												
Technology & Produc	Solutions	Phase -1 Phase -2												
		Treatment : Adult - Mild to Moderate	Treatment Children & Pediatric	Adjuvant : Pregnancy & Severity	Biomarker Validation treatment - Vulnerable for severity	Treatment for Coinfection & (metabolic) Comorbidity								
Tech	Proposed Dosage & Treatment duration	To be administered twice daily, in the morning and evening -7 days $+3$ days												
	Technology Validation		l Trial on COVID -19 Virus ompleted	Dengue In-vitro Assay confirms inhibition of all 4 serotypes with a selective Index > 400										
	Health Risk	128 у	ears Drug Existence	Low Risk of Developing Resistance Dual Action										
	Supply Chain	Readiness: Product Process validation completed and ready for commercial supply												

Process & Unmet Needs

	Team	Board & C-CAMP	Advisory Panel	Operation Experts	Project Management	Partner Management							
ise	Project Execution	In-vitro & Animal (Completed)	Clinical (Completed)	Manufacturing& Regulatory (Completed)	Patent, Commercial & Legal (Completed)	Business Partnering (Completed)							
Process & Expertise	Market Authorization Application – Regulatory Approval	Preclinical - Ready	Chemistry Manufacturing & Control - Ready	Animal Studies - In progress	Pharmacokinetic, Efficacy & Safety - POC - In progress	Phase - 3 Partnering (CSA & Industry)							
Pre	Market Access -Approval Route	India	World	Health Organization	Others Market								
	Project Timelines	Animal Studies Oct 2024	Clinical Trial Authorization – Oct/ Nov 2024	Pharmacokinetics - Jan 2025	POC - Efficacy & safety Studies - June 2025 & Apply for Emergency Approval	Phase – 3, Partnering - Dec 2025 followed by commercialization							
ering	Impact	141 countries	105 million impacted	36,000 fatalities	30 X over 50 years	No definitive treatment available							
Market & Partnering	Market Potential	Market value of US\$ 877.82 M in 2023 and is expected to accumulate a market value of US\$ 5,435.25 M (CAGR 20%) forecast period 2023-33.											
Market	Indirect Competition	Currently no approved Vaccine in India and few other countries two vaccines with restricted usage approval. Tetravalent Vaccines under development: 3 - 4 years to enter market											
	Direct Competition	6 - 8 Players global in the development Pipelines with repurposed and NCE category - Single action strategy											

Our Journey



Formulation Chemistry Manufacturing and Control	2017-18	
Manufacturing	Formulation	
	Manufacturing	

Technology platform

2017 10

Core IP Dosage

2019 - 2020

Company formation

Mgmt team

2019 - 20

Phase -1/2 POC Sars COV completed

> Batch I manufacturing

2021 - 22

Regulatory Meeting UK & Malaysia ,CDSCO Agency

Licensing for Manufacturing & CT- India

Revised Indication – Dengue

CMIE – AIIMS clinical Incubatee

C- CAMP Mentoring & Advisory www.welblu.com 2023-24

In-vitro Inhibition confirmed & Animal Model Studies in progress

WHO regulatory pathway – single for Phase -3 & product qualification

Regulatory Application Preparation

Clinical Trial preparation progress

CONFIDENTIAL

Project Road map

Key Tasks	2019 -22			2023			2024			2025				2026					
	Q 1 & 2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4
Technology Development & POC	*																		
Dengue Invitro Studies]														
Animal Model & Clinical – Dose Titration Studies																			
Phase – 3 Trail																			
REGULATORY (Pre- Submission) & FILING																			
Planning and Launch															4 P		T CO		
Ongoing Commercial Grade Production																		>>	Continu

CONFIDENTIAL

www.welblu.com

About Us

Focelite is dedicated to revolutionizing value chain strategies and solutions by harnessing decades of diverse expertise and accelerating partnerships between industry and institutes.

With a laser focus on optimizing every aspect of the value chain, across viral infection Focelite is committed to delivering innovative solutions that drive dengue treatment.

Strategy & Solutions

01

New product strategy to capture widespread market attention

O2 Product Innovation

Major partnership with industry leader to unlock opportunities O3 Revenue growth surpassed market expectations

Board Members





Mr. Rajendra Bhandari Chairman

More than 3 decade of Experience on setting up Pharmaceutical operations and partnering from Greenfield for various dosage form Vijay Kumar Ranka Managing Director

Molecular Biologist experienced from setting up complete research centre, specialized manufacturing catering to International market



Ms. Komal Minhas Strategic Partner

Microbiologist experienced in supply chain management , International Govt and NGO for product certification program, Trainer for Quality system



Dr. Vinayaka Srinivas CSO

Experienced developed cell biology technology platform & commercialization, Expertise in the development regulatory pathway of drug candidate



Dr. Praveen B Sancheti Clinical Advisor

More than 2 decade practise in surgery and managing Clinical drug programs. Expertise in infection management of pandemic in clinical setting



Mr. Rishav Saraf Financial Advisor

More than 2 decade of experience in auditing and compliance as per companies act . Expertise on in area of valuation



Our Mission

New cases of microbial infection and viral emergency are on the rise in diseases pose the greatest public health risk due to their epidemic potential and/or whether there is no or insufficient countermeasures.

At Focelite, with our research and development strategy teams, we develop anti - infective healthcare products, based on a multitarget approach enabled by the use of repurposed drugs in synergy with drug potential and benefitting from a high level of evidence of dual action.

Our goal: reduce the impact these diseases may have on millions of at-risk individuals, worldwide.

Focelite is a player committed to treatment, the spearhead of public health.

www.welblu.com

Thank You

- **L** Vijay Kumar Rank
- info@focelite.com
- www.welblu.com
- © 2024 Focelite Goodness India Pvt. Ltd. All Rights Reserved.



CONFIDENTIAL

www.welblu.com